WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Bundy family standoff: 10 years on, cattle graze disputed Nevada landAbortion: Progressive candidates share their stories after Roe's fallCommentary: Democracy a tool for U.S. to keep hegemony, incite divisionSenior Chinese leaders attend deliberations at annual legislative sessionOldest living conjoined twins, Lori and George Schappell, die at 62Commentary: Why will Chinese economy "genetically" rebound?To ensure that the global economy grows on right trackPerenara equals Super Rugby tryPresident Xi's Russia visit demonstrates a right path of stateChina to contribute wisdom, solutions to cause of peace, development for all humanity
2.5564s , 5888.515625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Earthly Echo news portal